Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702
Akira Inoue(Tohoku University Hospital), Toshihiro Nukiwa(Tohoku University), Naoto Morikawa(Tohoku University), Taku Nakagawa(Saint John's Health Center), Ichiro Kinoshita(Hokkaido University), Takashi Ishida(Keio University), Satoshi Oizumi(Hokkaido University), Kageaki Taima(Hirosaki University), Hiroshi Watanabe(Tohoku University), Shunichi Sugawara(Sendai Kousei Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Yoshiaki Mori(Iwate Prefectural Central Hospital), Ryota Saito(Tohoku University), Masao Harada(Shikoku Cancer Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 35
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953